Connor, Clark & Lunn Investment Management Ltd. Oramed Pharmaceuticals Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 107,062 shares of ORMP stock, worth $247,313. This represents 0.0% of its overall portfolio holdings.
Number of Shares
107,062
Previous 111,519
4.0%
Holding current value
$247,313
Previous $272,000
4.78%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ORMP
# of Institutions
66Shares Held
8.11MCall Options Held
17.4KPut Options Held
19.5K-
Bml Capital Management, LLC Zionsville, IN2.64MShares$6.11 Million3.97% of portfolio
-
Murchinson Ltd. Toronto, A61.75MShares$4.04 Million2.03% of portfolio
-
Boothbay Fund Management, LLC New York, NY845KShares$1.95 Million0.06% of portfolio
-
Morgan Jess S & CO Inc366KShares$846,3862.07% of portfolio
-
Rathbones Group PLC Liverpool, X0290KShares$669,4440.0% of portfolio
About ORAMED PHARMACEUTICALS INC.
- Ticker ORMP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,100
- Market Cap $89.7M
- Description
- Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...